Skip to main content
European Commission logo
Coronavirus Global R&I Collaboration Portal

Members

Members (21)

From across Europe and beyond, and from a variety of backgrounds, our members share many common goals. Our members’ diversity, expertise and openness to collaborate is our strength. Search our members list here. Filter using our search options. All members are encouraged to network and develop as a community that fosters collaboration. Find your match, share, engage and complement expertise.

Showing 1-10 of 21 members.

Micar Innovation (Micar21)

Business enterprise
Home country
Bulgaria
Type of research activities
Applied research, Experimental development
Fields of research
Natural sciences, Medical and health sciences, Agricultural and veterinary sciences
Specialisation and expertise

The aim of Micar21 is to provide urgently high quality data about the effect of the Next Covid-19 mutations.

We want to provide example of science validation of the capability and speed of Micar21 Drug Discovery Platform, which can be viewed and validated through science publications. Early of December no one had accurate data on the effect of the new Covid19 - UK & South Africa mutations on the action of vaccines and on the binding of the virus to ACE2, so Micar21 decided to calculate pro-bono and support science worldwide. On 16.12.2020 - Micar21 starts insilico calculations. On 26.12.2020 - first version of our science publication - with calculation for English mutation COVID19. On 31.12.2020 - second version of our science publication - with calculation for South African mutation COVID19 is included and we published our scientific publication: https://www.biorxiv.org/content/10.1101/2020.12.23.424283v2.article-metrics Dr. Filip Fratev (Micar21) is the sole author of the science publication. In less than 5 months there are already 22 citations (very good result). Our competitors appeared with insilico data for Covid19 Mutations at the end of January 2021 (can be traced through science publications) On 14.02.2021 (sent on 14.02.2021 - published on 23.02.2021) science publication by Oxford, validates Micar21 insilico results with experimental data: https://www.cell.com/cell/pdf/S0092-8674(21)00226-9.pdf Here, through the experimental data, our Micar21 insilico data calculated in December 2020 are proved. Micar21 predicted in silico the stronger N501Y mutant binding to ACE2 (-1.42 kcal/mol) whereas months later experimental data shown a value of (-1.40 kcal/mol), thus, confirming that our in silico results was precise. The aim of Micar21 study and new paper was to provide urgently high quality data about the effect of the UK and South African mutations. However, during the process of revision of the paper many experimental studies became available which was an excellent opportunity for a validation of the in silico approaches employed here and in particular protein-protein FEP. Also, we can compare our results to other data obtained by theoretical approaches which can be viewed and validated through other science publications and showed in our new science publication in Journal of Chemical Information and Modelling - under final review: http://micar21.com/Covid19_UK_SA_mutation.pdf

22 NOV 2021 Micar21 publish at Journal of Chemical Information and Modeling

N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study

https://pubs.acs.org/doi/10.1021/acs.jcim.1c01242 

 

27 Nov 2021 / 3:08 CET  Filip Fratev / Micar Innovation (Micar21)

We plan to calculate the binding to ACE2 of all individual B.1.1.529 mutations and their total effect.

The new B.1.1.529 SARS-CoV-2 lineage (Omicron) looks really terrible with totally 7 mutations located at the RBD-ACE2 binding surface. To urgently provide a high quality data we are performing with Suman Sirimulla (UTEP) a Free energy of Perturbation (FEP) assessments of the impact of all mutations. The FEP method has been shown in our previous studies to be highly accurate for Alpha (1) and Mu (2) variants. We have already calculated that the G496S mutation lead to an additional increase in the RBD-ACE2 binding by 4 times in comparison to the presence of only N501Y mutation (Alpha variant). The latter mutation is included in our set up, thus we can conclude that G496S plus N501Y mutations result in a totally of 11 times increase of the RBD-ACE2 binding.

We plan to calculate the binding to ACE2 of all individual B.1.1.529 mutations and their total effect. Also, we will assay how these mutations will impact various antibody classes. We will keep you updated!

(1) N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study - https://pubs.acs.org/doi/10.1021/acs.jcim.1c01242 The N501Y and K417N mutations in the spike protein of SARS-CoV-2 alter the interactions with both hACE2 and human derived antibody: A Free energy of perturbation study - https://www.biorxiv.org/content/10.1101/2020.12.23.424283v2

(2) - The R346K Mutation in the Mu Variant of SARS-CoV-2 Alter the Interactions with Monoclonal Antibodies from Class 2: A Free Energy of Perturbation Study - https://www.biorxiv.org/content/10.1101/2021.10.12.463781v1

https://www.linkedin.com/feed/update/urn%3Ali%3Aactivity%3A6870177115547963392/

 

28 Nov 2021 / 6:24 CET  Filip Fratev / Micar Innovation (Micar21)

Our preliminary FEP data showed that the SARS-CoV-2 Omicron’s (B.1.1.529 lineage) Q498R, Y505H and G496S mutations drastically increase the binding to ACE2, which is an indication of its transmission.

Our preliminary FEP data showed that the SARS-CoV-2 Omicron’s (B.1.1.529 lineage) Q498R, Y505H and G496S mutations drastically increase the binding to ACE2, which is an indication of its transmission. They enhanced the binding by 98, 14 and 13 times, respectively, which transforms the S1-RBD to a picomolar binder! Our estimations are based on the structures of both Alpha and Beta variants. The K417N and T478K had a relatively small negative effect to the binding: ddG=0.44 and +0.16 kacl/mol, respectively. Initially, we are calculating the contribution of the individual mutations to the RBD-ACE2 interactions and next we will do that for their total cumulative effect. Also, we expect an improvements of the results after the multi-site FEP calculations due to the cycle closure data. Currently, we observed a difference only for G496S which has a ddG= -0.82 and -0.23 kcal/mol in Alpha and Beta variants, most likely due to the not good convergence in Beta. We will improve that during the next hours and expect the data for Q493K. The latter and Glu484Ala and Lys417Asn can be described as an individual hot spot of mutations.

https://www.linkedin.com/feed/update/urn:li:activity:6870177115547963392/

 

 29 Nov 2021 / 6:49 CET  Filip Fratev / Micar Innovation (Micar21)

We received the all FEP data for the Omicron’s RBD-ACE2 binding. It is clear now that the Q498R and Q493K are the main players in these interactions.

We received almost the all FEP data for the Omicron’s RBD-ACE2 binding. It is clear now that the Q498R and Q493K are the main players in these interactions. However, there is a competition between them leading to decrease of the total binding; i.e. similar to case of N501Y and K417N tandem of mutations in Beta variant. What is exactly this decrease we will know soon but the ddG of Q493K has a positive value. The transformation of not charged to charged residues in known to produce a significant bias in FEP calculations. This is valid indeed for both Q498R and Q493K. Thus, we developing a special protocol in order to describe these significant changes which are responsible for the RBD-ACE2 binding in Omicron. In addition, our results shown that the N440K and G446S have indeed a small effect to the RBD-ACE2 interactions and the ddG values were -0.2 and +0.21 kcal/mol; i.e. in frame of possible error. We expected the G446S in a combination with G498R and surrounding residues additionally may stabilize this constellation of harmful mutations and in particular Arg498 but this turn out to be not true (ddG=0.24).

https://www.linkedin.com/feed/update/urn:li:activity:6870982318018854912/

Language(s)
English

Matvey Sprindzuk

Business enterprise
Home country
Belarus
Type of research activities
Applied research, Basic research, Experimental development
Fields of research
Natural sciences, Engineering and technology, Medical and health sciences
Specialisation and expertise
Bioinformatics, genomics, medicine, virology, microbiology, image processing, AI, software engineering, COVID-19, tuberculosis, mathematical modelling, applied mathematics, medical systems, data processing automation
Language(s)
English

SHINE 2Europe, Lda

Business enterprise
Home country
Portugal
Type of research activities
Applied research, Basic research, Experimental development
Fields of research
Psychology and cognitive sciences, Economics and Business, Education, Sociology, Law, Political science, Other social sciences, Medical and health sciences, Humanities and the arts
Specialisation and expertise
SHINE's main goal is to promote inclusive societies for all. This includes gender, race, age, personal opinions and lifestyles, literacy, environment and sustainability, with shared responsibility between all citizens and within democratic values. This is not restricted to awareness raising, advocating for the most fragile citizens or calling up the public attention to all the needs for extra care and specific interventions. What we really foster is to help imagining a society that is already built taking into consideration the different needs of all citizens and creating holistic solutions that can help them to be happy and have a fulfilled life. In this concept we include: • strengthening organisations roles and initiatives that enhance inclusion, active and participatory citizenship, human rights, health and care for the frailest, quality education and training. • promoting entrepreneurship, sustainable innovation and market outreach, through targeted impacts on different ecosystem layers. • directly engaging with stakeholders, end-users and citizens in co-creating, experimenting and validating innovative ideas and products, favouring citizen involvement in public decision-making. • creating training materials and tools that promote lifelong learning and self-development, peer-learning and enhanced literacy and skills in different target groups. • advancing knowledge on age-friendly, inclusive, green and tech-savvy societies, promoting research and publications on these themes. • on a higher level, working in strategies, policies and participatory approaches that lead to a better democratic process, empowering citizens and engaging the whole cycle of stakeholders. Bringing innovation, digital solutions, social inclusion and a greener environment is often mainly dependent of policy change. With all the differences between regions, countries and public systems, one size does not fit all. Policy change requires a complex, bureaucratic and long process, implies connecting a broad network of actors and moreover, implies finding public commitments, which is not simple or easy. SHINE’s team has a solid experience and a wide network of contacts both in national and international contexts, that ensure the better way through to build policy claims. Although this is not the core focus of SHINE, the creation, development or adaptation of simple IT solutions is also one of our key assets. Whenever it makes sense to provide an integrated solution for a societal challenge that can be adequately addressed by a digital product, e.g. an app, a game or a platform, SHINE has the expertise to deliver it too. What are the gains? We can talk both languages and approach the different worlds - technological, societal and research and bridge the gap that so many times makes innovation fail in the final run. Key areas of expertise • Ethical excellence • Co-creation and stakeholder engagement, citizen science, RRI • Policy recommendations • Training, literacy and citizen empowerment • Societal impact analysis • Dissemination and outreach • Entrepreneurship and sustainable innovation • Health and digital solutions • Data sharing governance
Language(s)
English, Portuguese

PREDICTA S.A.

Business enterprise
Home country
Greece
Type of research activities
Applied research, Basic research
Fields of research
Economics and Business, Engineering and technology, Medical and health sciences
Specialisation and expertise

Consulting / Advisory Services areas: • Big Data Strategy design • Analytics Applications’ roadmap design • Wider Analytics technology infrastructure architectural design and implementation • Analytics’ neighboring domains roadmap design, i.e. Loyalty Scheme design and implementation, Marketing Automation/Campaign Management systems, Mobile Applications’ hosting/integrating technologies, … Professional Implementation Services Generic Analytics Applications & Methodologies: • Value-based Segmentation or/and RFM Analysis • Behavioral Segmentation Analysis • Strategic Segmentation Analysis • Next Best Offer Analysis • Cross/Up/Deep-Selling Propensity Modeling • Early Warnings on Signs of Customers’ Defection Analysis • Anti-Attrition / Churn Propensity Modeling • Social Network Analysis (SNA) • Forecasting Analysis • Credit Risk Modeling (PD, LGD, …) • Pre-Collections & Collections Modeling Industry-specific Analytical Solutions: • Total Enterprise Streamlined Customer Management for Next Best Action (NBA) • Performance Forecasting & Distribution Network Target Allocation • Customer Lending Optimization (CLO) • Geolocation Analytics for Cards’ transactions’ boosting, penetrating loyalty partners’ network (merchants) • Customer “Digitalization” Solution • Customer Onboarding Strategy Solution • Complaints Management via Text Analytics • Streamlined solution for IFRS9 Risk Regulatory Framework compliance and overall processes management.

Language(s)
English

Covidpedia Labs

Business enterprise
Home country
Belgium
Type of research activities
Applied research, Basic research, Experimental development
Fields of research
Education, Sociology, Political science, Media and communications, Medical and health sciences, Humanities and the arts
Specialisation and expertise
Covidpedia Labs is an extensive platform on the COVID-19 pandemic - the platform distils and detangles information that is misleading or intentionally disinforming people; releases up to date information on the pandemic; and scientific reporting.
Language(s)
English, English, French

Kubilay Boya

Business enterprise
Home country
Turkey
Type of research activities
Applied research, Experimental development
Fields of research
Natural sciences, Engineering and technology
Specialisation and expertise
The R&D team of Kubilay Boya currently consists of 1 PhD, 4 MSc, 10 BSc and 3 AS level researchers. Paint and coatings research is an interdisciplinary subject, it combines chemistry, chemical engineering, polymer science and technology and materials science. Our team in Kubilay Boya has chemists, chemical engineers and polymer scientists, reflecting the diverse nature of paint and coatings. They are specialists in design and scaling-up new formulations, chemical and physical analysis of wet paints and dried coating films, resin synthesis, structural elucidation methods including Gas Chromatography and Fourier-Transform Infrared Spectroscopy.Since its first production back in 2005, Kubilay Boya participated in several R&D projects supported by The Scientific and Technological Research Council of Turkey (TÜBİTAK). These projects include Toluene Diisocyanate (TDI) Prepolymer Synthesis, Environment-Friendly Low-Lead Mirror Backing Paint, Epoxy Acrylate Oligomer Synthesis. Furthermore, studies to develop an antiviral wood coating system which has efficacy against enveloped positive-sense single-stranded RNA viruses such as SARS-CoV-2, the virus causing COVID-19 are ongoing at Kubilay Boya R&D facilities.
Language(s)
English, Turkish

Prof. Laura Lechuga - NanoBiosensors and Bioanalytical Applications -

Government & public sector
Home country
Spain
Type of research activities
Applied research, Experimental development
Fields of research
Engineering and technology, Medical and health sciences
Specialisation and expertise

Our activity encompasses the entire process of generating new photonic biosensor devices, including fundamental research and theoretical design, nanofabrication, surface biofunctionalization, lab-on-a-chip integration, and their final validation in real scenarios. We have widely demonstrated our expertise in:

  • Surface Plasmon Resonance (SPR and LSPR) biosensors: design and development of portable devices with user-friendly operation and high performance.
  • Bimodal Waveguide (BiMW) biosensors: our pioneering design of interferometric nanophotonic system for ultrasensitive label-free analysis.
  • Sensor biofunctionalization: unique know-how on gold and silicon surface chemistry strategies for controlled and optimum bioreceptor immobilization, including proteins, antibodies, and oligonucleotides.
  • Biomedical applications: assay development and clinical validation for diagnostics and therapy monitoring of different diseases and disorders, including cancer, infections, celiac disease, allergies, etc. Our biosensors have been successfully applied for detection of proteins, antibodies, microRNA, pathogens (virus and bacteria), peptides, drugs, and also epigenetic biomarkers (alternative splicing, DNA methylation, etc.).
  • Environmental applications: assay development and validation for detection and monitoring of pollutants and contaminants in water, food, etc.
Language(s)
English, Spanish
The portal is now open.

Join this community of researchers, publish your member profile and team up for new collaboration opportunities.

Become a member